Clinical Trials
Registry participants may be eligible for clinical trials testing new treatments for bronchiectasis and NTM. Explore active studies and learn how to participate.
Recruiting
This Phase 3 trial is evaluating brensocatib, a potential first FDA-approved treatment for bronchiectasis. The study examines the drug's effectiveness in reducing exacerbations and improving quality of life.
Insmed Incorporated
Recruiting
Calgary, AB + Multiple Sites
Join the Registry
By joining our registry, you contribute to groundbreaking research that could lead to new treatments and better outcomes for thousands of patients.
Reach out to our research coordinators to express interest and ask questions.
Our team will review your medical history to confirm eligibility criteria.
Review and sign the consent form after discussing the study with our team.
Complete initial assessments and begin contributing to vital research.
Ready to participate?
Have questions about eligibility, trials, or the enrollment process? Our team is here to help.